Home » Stocks » AGTC

Applied Genetic Technologies Corporation (AGTC)

Stock Price: $5.81 USD 0.30 (5.44%)
Updated Mar 2, 2021 4:00 PM EST - Market closed
After-hours: $5.82 +0.01 (0.17%) Mar 2, 7:58 PM
Market Cap 248.27M
Revenue (ttm) n/a
Net Income (ttm) -56.53M
Shares Out 25.88M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $5.81
Previous Close $5.51
Change ($) 0.30
Change (%) 5.44%
Day's Open 5.75
Day's Range 5.66 - 6.10
Day's Volume 3,245,465
52-Week Range 2.29 - 9.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

Article reflects Company's leadership and innovation in scalable, reproducible manufacture of adeno-associated virus (AAV)-based gene therapies

GlobeNewsWire - 3 weeks ago

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of a...

GlobeNewsWire - 1 month ago

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of ...

GlobeNewsWire - 1 month ago

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of ...

GlobeNewsWire - 1 month ago

-Preliminary results suggest sustained improvements to 12-months in visual sensitivity, as measured by full field static perimetry, supported in some patients by other endpoints- -Company plan...

GlobeNewsWire - 1 month ago

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associate...

Zacks Investment Research - 3 months ago

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -17.65% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies...

GlobeNewsWire - 3 months ago

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of a...

GlobeNewsWire - 3 months ago

- Durable improvements observed in visual sensitivity and visual acuity over a wide dose-range with a favorable safety profile -

GlobeNewsWire - 3 months ago

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of a...

GlobeNewsWire - 4 months ago

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associat...

GlobeNewsWire - 4 months ago

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associate...

GlobeNewsWire - 4 months ago

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC), Blueprint Genetics, and Foundation Fighting Blindness, announce toda...

Seeking Alpha - 5 months ago

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

- Planned Phase 2/3 trial expected to include approximately 60 patients and a responder analysis based on at least 7 decibel improvement in visual sensitivity in at least 5 loci across two act...

GlobeNewsWire - 5 months ago

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-assoc...

GlobeNewsWire - 6 months ago

Preclinical studies validate the transgene and dosing used in the ongoing Phase 1/2 clinical trial in patients with XLRP due to mutations in the RPGR gene Preclinical studies validate the tran...

GlobeNewsWire - 6 months ago

Patient Advisory Council to include advocates from the inherited retinal diseases global community

Newsfile Corp - 6 months ago

Washington D.C--(Newsfile Corp. - August 4, 2020) - At today’s meeting of the Small Business Capital Formation Advisory Committee, the Securities and Exchange Commission announced the appointm...

GlobeNewsWire - 7 months ago

FDA feedback allows for forward program development

Zacks Investment Research - 8 months ago

Does Applied Genetic Technologies (AGTC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 8 months ago

Is (AGTC) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 8 months ago

Applied Genetic (AGTC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

GlobeNewsWire - 8 months ago

GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials o...

GlobeNewsWire - 8 months ago

Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials

GlobeNewsWire - 8 months ago

GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials o...

GlobeNewsWire - 8 months ago

Mobile vision testing unit enables X-linked retinitis pigmentosa and achromatopsia clinical trial patients to maintain important scheduled study assessments during COVID-19 pandemic

Forbes - 8 months ago

If you’re looking to hedge your portfolio to protect some downside, or make some bets against high valuations, our deep learning algorithms have paired with our Artificial Intelligence (“AI”) ...

Other stocks mentioned: PHUN, SEAS, SIX, TPR
Zacks Investment Research - 9 months ago

The Applied Genetic Technologies (AGTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 9 months ago

Applied Genetic Technologies (AGTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 9 months ago

Is (AGTC) Outperforming Other Medical Stocks This Year?

Seeking Alpha - 9 months ago

Applied Genetic Reports Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

GlobeNewsWire - 9 months ago

 -  Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect i...

Seeking Alpha - 9 months ago

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of 9.09% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead...

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in Applied Genetic Technologies.

Zacks Investment Research - 10 months ago

Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 11 months ago

Applied Genetic Technologies (AGTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 11 months ago

Enrollment ongoing in pediatric dose groups

GlobeNewsWire - 1 year ago

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...

GlobeNewsWire - 1 year ago

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...

GlobeNewsWire - 1 year ago

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of...

Benzinga - 1 year ago

In the last year, sell-side analysts have shown confidence in Applied Genetic Technologies Corp (NASDAQ: AGTC) with a series of upgrades and initiations.

Benzinga - 1 year ago

Shares of Applied Genetic Technologies Corp (NASDAQ: AGTC) are tumbling Thursday despite the company reporting encouraging results from an Phase 1/2 study.

24/7 Wall Street - 1 year ago

Applied Genetic Technologies Corp. (NASDAQ: AGTC) shares were crushed early Thursday after the firm reported interim data from its midstage trial in patients with achromatopsia.

GlobeNewsWire - 1 year ago

–Encouraging preliminary signs of biologic activity and a favorable safety profile are outcomes that are clinically relevant to patients

Seeking Alpha - 1 year ago

Applied Genetic Technologies Should Be On Your Radar After Latest Rare Disease Eye Data

Zacks Investment Research - 1 year ago

Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Applied Genetic Technologies (AGTC) stock based on the movements in the options market lately.

24/7 Wall Street - 1 year ago

Applied Genetic Technologies Corp. (NASDAQ: AGTC) shares jumped by more than 50% on Thursday after the firm announced positive interim data from its midstage trial in X-linked retinitis pigmen...

About AGTC

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. I... [Read more...]

Industry
Biotechnology
IPO Date
Mar 27, 2014
CEO
Susan Washer
Employees
83
Stock Exchange
NASDAQ
Ticker Symbol
AGTC
Full Company Profile

Financial Performance

In 2020, AGTC's revenue was $2.45 million, a decrease of -94.12% compared to the previous year's $41.69 million. Losses were -$45.89 million, 2,187.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for AGTC stock is "Strong Buy." The 12-month stock price forecast is 17.67, which is an increase of 204.13% from the latest price.

Price Target
$17.67
(204.13% upside)
Analyst Consensus: Strong Buy